Affordable Access

deepdyve-link
Publisher Website

Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options.

Authors
  • Aviv, A
  • Tadmor, T
  • Polliack, A
Type
Published Article
Journal
Annals of Oncology
Publisher
Oxford University Press
Publication Date
Sep 01, 2013
Volume
24
Issue
9
Pages
2236–2244
Identifiers
DOI: 10.1093/annonc/mdt192
PMID: 23712546
Source
Medline
Keywords
License
Unknown

Abstract

Primary breast lymphoma is a rare form of non-Hodgkin lymphoma with some distinct clinical features. The most common histopathological type is diffuse large B-cell lymphoma (DLBCL), but other less frequent subtypes are also encountered. In this review, we describe the characteristics of primary breast DLBCL, with emphasis on pathogenesis, staging, risk stratification and prognosis. In addition, key issues regarding therapy and various available therapeutic modalities are addressed, as well as the role of rituximab in therapy and whether central nervous system prophylaxis is still routinely required. There are very few prospective clinical studies addressing therapy, and available data rely mostly on retrospective case series involving small numbers of patients. Our conclusions and proposed recommendations are therefore not offered as formal guidelines. This review attempts to represent an unbiased analysis of the published data and is intended as a useful aid for clinicians treating this uncommon type of extra nodal lymphoma.

Report this publication

Statistics

Seen <100 times